STAT+: Generic makers fall short when providing access to low- and middle-income countries, analysis finds
A handful of the largest purveyors of generic medicines have made only halting progress to…
Category: Pharmaceuticals
STAT+: GOP senator probes drug discount programs at Cleveland Clinic, Bon Secours
WASHINGTON — The top ranking Republican on the Senate health committee is launching an investigation…
STAT+: Drug industry payments to eye docs boosted Medicare spending on pricier treatments
Ophthalmologists who accepted payments from drug companies were less likely to prescribe a cheaper medicine…
A STAT analysis shows how top drug companies are starting to take action on climate
This article is adapted from STAT’s exclusive analysis in the STAT Report: “Climate rankings: How top…
.jpg)
STAT+: 6 ways the government could help address drug shortages, including in cancer
WASHINGTON — Republicans and Democrats alike want to stop drug shortages from happening. The vexing…
STAT+: Biogen shutters digital health group, nixes Apple study, as part of cost cuts
Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person…
Octopus tentacles inspired a new drug delivery patch that sticks to the inside of your cheek
The story of the latest development in drug administration technology — a mouth patch that…
STAT+: Over-the-counter Sudafed doesn’t work. Neither does our system for evaluating older drugs
You would have been forgiven for being surprised on Sept. 12 when a panel of…
STAT+: The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she’s been edged out of the story
On a mild May day in 1993, about 60 scientists and doctors gathered on a…
STAT+: Just how much money do drugmakers gain from patent extensions?
Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so…
STAT+: With Menendez indictment, pharmaceutical industry could lose a key ally
WASHINGTON — With mounting calls for embattled Sen. Bob Menendez to resign, the pharmaceutical industry…
Will a government shutdown stall Medicare drug price negotiations?
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
STAT+: What ever happened to biotech’s big comeback?
This was supposed to be the year of the biotech comeback, when promising new medicines…
STAT+: Cancer drug shortages widen disparities between big systems and small
For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies…
Senate HELP on collision course
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval
Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly…
STAT+: Approval setback for EpiPen alternative puts spotlight on common anti-competition tactic
Americans who suffer severe allergic reactions won’t have alternatives to autoinjectors like the Epipen for…
STAT+: Hearing on Medicare drug price negotiation gets unusually heated
WASHINGTON — Republicans and Democrats fought it out over Medicare drug price negotiation Wednesday at…
STAT+: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions
For the fourth time this year, Novartis has been reprimanded by a U.K. trade group…
STAT+: A breakthrough cystic fibrosis drug gave them the gift of time. But miracles come with complications.
The small box full of promises arrived at Jessica Anderson’s home on her 31st birthday….
STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro
As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding…
STAT+: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind
Apellis Pharmaceuticals has been slowly rebounding from an unjustified safety scare related to its approved…
STAT+: How a cash-prize system that phases out patents may lower drug prices
Two months ago, Sen. Bernie Sanders (I-Vt.) moved a step closer to an idea he…
STAT+: PBMs were the target of House hearing, but pharma wasn’t spared criticism
WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of…
STAT+: Chamber of Commerce, government clash at first court hearing on Medicare drug prices
WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday…
Johnson & Johnson is getting rid of its script logo after more than 130 years
Johnson & Johnson is signing off on a new logo. The health care giant said…
STAT+: House subcommittee forays into fixing drug shortages
WASHINGTON — A House subcommittee took a first step today toward legislation to fix drug…
STAT+: FTC warns drugmakers they can face legal action over improper patent filings
The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly…
STAT+: Medicare is urged to monitor how rebates affect Part D drug spending, but agency demurs
The U.S. government should monitor the effect that rebates have on Medicare Part D plans…
Novelist John Green launches attack on Cepheid over the price of its TB test
John Green, a novelist and high-profile YouTuber, is once again leveraging his star power in…
STAT+: FDA panel endorses Alnylam’s heart drug — after picking apart its supporting data
A group of advisers to the Food and Drug Administration voted in favor of Alnylam…
STAT+: Lawmakers introduce bill to require drugmakers to provide key info to both FDA and U.S. Patent Office
Amid concerns over monopolies held by drugmakers, a bipartisan group of lawmakers introduced a bill…
Popular nasal decongestant doesn’t actually relieve congestion, FDA experts say
WASHINGTON — The leading decongestant used by millions of Americans looking for relief from a…
STAT+: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to…
.jpg)
Opinion: Patients might finally receive practical information with prescriptions — if the FDA doesn’t blow it
Patients often ask two questions about every medical treatment: Will it help me? Will it…
STAT+: Here are the dozens of weight loss drugs in development to catch a booming market
The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit…
STAT+: Crinetics acromegaly drug succeeds in late-stage trial but would face stiff competition if approved
SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a…
Opinion: STAT+: Sanofi CEO Paul Hudson: The right way to bring AI into pharma
While it’s widely accepted that the pharma industry is innovative in R&D, it is also…
Biotech execs vie for a share of obesity drug boom: ‘It’s the early innings’
Pharma giants Novo Nordisk and Eli Lilly might’ve led the way into a new era…
STAT+: Amazon’s chief medical officers on where the company’s health care bets are headed next
The graveyard is littered with Amazon’s bets in health care: wearables, Care, the ill-fated Haven….
STAT+: Why the drug industry’s opaque warnings on price negotiations fall short
Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry…
STAT+: AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing bill’s alleged cancer problem
Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a…
STAT+: Cancer care appears brighter as off-the-shelf CAR-T advances
If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future…
STAT+: FTC settles with Amgen over $28 billion deal for Horizon
After months of legal sparring, Amgen and Horizon Therapeutics settled a lawsuit with the U.S….
STAT+: AstraZeneca bets that gene therapy’s workhorse will still deliver the goods
Seng Cheng has been working in gene therapy for nearly as long as gene therapy…
STAT+: One dose of psilocybin may have lasting effects on major depression, study finds
A single dose of psilocybin may have enduring benefits for people with major depressive disorder,…
STAT+: J&J cuts the price of its life-saving TB pill by more than half for many low and middle-income countries
Amid controversy over access to a life-saving tuberculosis pill, a new contracting effort is expected…
STAT+: FDA delays enforcement of a pharmaceutical supply chain law to stop counterfeit drugs
In response to growing complaints, the U.S. Food and Drug Administration has postponed its plans…
STAT+: AstraZeneca sues to immediately stop Medicare drug price negotiation program
WASHINGTON — AstraZeneca is the sixth drug maker to pile on a legal challenge to…
STAT+: Pharmalittle: This fall’s COVID booster rollout; approval for Pfizer’s RSV vaccine
Good morning Pharmalittle students. This is Allison DeAngelis, filling in for Ed Silverman while he’s…